Learn More
SNMMI Therapeutics Conference Rescheduled for March 2022
With the health and safety of members, volunteers, and attendees in mind, SNMMI made the decision to reschedule the SNMMI Therapeutics Conference, originally scheduled for November 11-13, 2021. The SNMMI Therapeutics Conference will now take place March 10-12, 2022, in New Orleans, LA. Read the full date change announcement.
Special Offer on SNMMI's Nuclear Medicine Review Course: September 11-12, 2021
SNMMI members can save 50% when they register to attend SNMMI's Online Nuclear Medicine Review Course and in-training resident members can register for free. This two-day course is the perfect resource to help you prepare for your board exam or use as a great general refresher to enhance your practice! Register.
Save the Date: 2022 SNMMI Mid-Winter and ACNM Annual Meeting.
ACNM Annual Meeting abstract submission window opens in September. Sign up to be contacted when more information becomes available for 2022 SNMMI Mid-Winter and ACNM Annual Meeting.
Healthcare Provider
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
- What's New
- Disease-Specific Information
- Guidelines
- Ordering Information
- Other Resources
- Request a Speaker
SNMMI's Newly Approved Appropriate Use Criteria
Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
NEW AUCs:
- PET Myocardial Perfusion Imaging (MPI)
- Imaging Evaluation of Biochemical Recurrence of Prostate Cancer Following Definitive Primary Treatment
• Click here for a printer friendly Fact Sheet version - Nuclear Medicine in Evaluation and Treatment of Differentiated Thyroid Cancer
- Gastrointestinal Transit
• Click here for a printer friendly Fact Sheet version - Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
- Hepatobiliary Scintigraphy in Abdominal Pain
- FDG PET/CT Restaging and Response Assessment of Malignant Disease
- Bone Scintigraphy in Prostate and Breast Cancer
- Ventilation/Perfusion (V/Q) Imaging in Pulmonary Embolism
Disease-Specific Information
Oncology |
Cardiology
|
Neurology
|
Guidance
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
Guidelines
Appropriate Use Criteria
Dosimetry
Dose Optimization
Related Resources
NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary
Ordering Information
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
-
Sample Request Forms
-
Sample Letters of Medical Necessity
-
Sample Reports from Nuclear Medicine Physician
-
CMS Decision Memos
Learn More
Other Resources
Request a Speaker
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
Outreach Speaker Request Form
Outreach Program
FAQs
- June 27, 2022 —
Aetna Reverses Cardiac PET/CT Non-Coverage & Updates Policy for PSMA Therapy
SNMMI and ASNC requested that Aetna reverse its non-coverage cardiac PET/CT policy. We are thrilled to communicate that within a few days of receiving our letter, Aetna reversed the policy. Also, Aetna recently updated and published their coverage policy for PSMA imaging for PLUVICTO therapy eligibility.
(Government Relations News) - April 28, 2022 —
SNMMI and Partners Request a Hearing for the FIND Act
This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.
(Government Relations News) - February 18, 2022 —
SNMMI Congratulates FDA Commissioner Califf
SNMMI congratulates Robert Califf, MD, on his confirmation as the 25th Commissioner of the U.S. Food and Drug Administration.
(Government Relations News) - February 17, 2022 —
SNMMI Advocates for Expanded Coverage & Reimbursement of Amyloid PET
When CMS issued a national coverage determination analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, SNMMI took action.
(Government Relations News)
- Jun 8, 2024 -
Jun 11, 2024
—
SNMMI 2024 Annual Meeting
Metro Toronto Convention Centre
Headquarter Hotel: Fairmont Royal York | Toronto | Canada
Featured Resources
- Legislative Issues
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
- Celebrate Women in Medicine Month
- Radiation Safety+ Review and Essentials
- Clincal Guidelines
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
- Webinars